Overall survival (OS) in women with genital tract melanoma (GTM) is improved with immunotherapy, according to study findings published in Melanoma Research.
Of Interest
Exploring the Long-Term Psychosocial Impacts of Stage IV Melanoma in Survivors
Stage IV melanoma survivors face persistent adverse effects and distress, highlighting the need for targeted psychological support and care.
ctDNA Monitoring Can Predict Early Melanoma Recurrence Following Resection
Data come from patients with stage 3 melanoma enrolled in a phase 3 randomized trial and showed that detection of circulating tumor DNA (ctDNA) prior to adjuvant systemic therapy can predict risk of early recurrence.
RP1 Plus Nivolumab Represents the Next Frontier of Oncolytic Virus–Based Therapy for Melanoma
Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.